tirzepatide fda approved weight loss for Eli Lilly's weight-loss pill is

Background Over the coming years, the market for anti-obesity medicines (AOMs), including glucagon-like peptide-1 (GLP-1) receptor agonists, is projected to grow more rapidly in ex-US markets than in the US

Cardiovascular Effects Dose-dependent increases in heart rate were observed with retatrutide: Heart rate increases peaked at approximately 24 weeks Gradually declined thereafter while remaining elevated above baseline This pattern is similar to that observed with other GLP-1 receptor agonists[4] The clinical significance of these heart rate changes requires further evaluation in larger and longer-term studies

Glucagon-like peptide 1 (GLP-1) is an incretin hormone released from the gut in response to food intake

Semaglutide treatment duration varies by individual health goals and response, typically spanning months to years

Prescription product

Circana studied changes in purchases and consumption among GLP-1 users and identified marked differences in behavior during the first three months of GLP-1 usage versus months 10-12